Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $10.3 million.

  • Cumberland Pharmaceuticals' Operating Expenses fell 484.81% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 633.76%. This contributed to the annual value of $44.3 million for FY2024, which is 978.84% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Operating Expenses of $10.3 million as of Q3 2025, which was down 484.81% from $11.6 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Operating Expenses peaked at $15.5 million during Q4 2023, and registered a low of $9.6 million during Q3 2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' median Operating Expenses value was $10.9 million (recorded in 2024), while the average stood at $11.4 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Operating Expenses surged by 3623.06% in 2023, and later crashed by 2095.44% in 2024.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Operating Expenses stood at $12.7 million in 2021, then dropped by 10.04% to $11.4 million in 2022, then soared by 36.23% to $15.5 million in 2023, then decreased by 20.95% to $12.3 million in 2024, then decreased by 16.45% to $10.3 million in 2025.
  • Its Operating Expenses stands at $10.3 million for Q3 2025, versus $11.6 million for Q2 2025 and $10.4 million for Q1 2025.